Sfoglia per AUTORE
GRIESSHAMMER M
Collezione AOU Città della Salute di Torino

  

Items : 8

Breakthrough infections in MPN-COVID vaccinated patients. in Blood cancer journal / Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8.
2022
AOU Città della Salute di Torino
AOU Novara

Curto-Garcia N; Carbonell S; Cavalca F; Borsani O; Bucelli C; Betti S; Kulikowska de Na??cz A; Cattaneo D; Guenova M; Navas Elorza B; Cichocka E; Angona A; Kusec R; Xicoy Cirici B; Sagues Serrano M; Carli G; Lopez Abadia E; Sanchez AM; Hernandez-Boluda JC; Garcia-Gutierrez V; Quiroz Cervantes K; Griesshammer M; Heidel FH; Bolaños Calderón E; Kiladjian JJ; Koschmieder S; Magro Mazo E; Foncillas MA; Osorio S; et alii...

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. in American journal of hematology / Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27.
2022
AOU Città della Salute di Torino
AOU Novara

Curto-Garcia N; Rambaldi A; Betti S; Bellini M; Borsani O; Cavalca F; Cichocka E; Cattaneo D; de Na??cz AK; Bucelli C; Koschmieder S; Navas Elorza B; Angona A; Xicoy Cirici B; Lopez Abadia E; Sagues Serrano M; Kusec R; Osorio S; Carreno-Tarragona G; Hernandez-Boluda JC; Magro Mazo E; Carli G; Garcia-Gutierrez V; Marin Sanchez A; Patriarca A; Quiroz Cervantes K; Griesshammer M; Bolaños Calderón E; Kiladjian JJ; et alii...

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. in Leukemia / Leukemia. 2021 Oct;35(10):2989-2993. doi: 10.1038/s41375-021-01279-1. Epub 2021 May 19.
2021
AOU Città della Salute di Torino

Vianelli N; Arellano-Rodrigo E; Mannelli L; Cattaneo D; Betti S; Falanga A; Goel S; Ianotto JC; Benevolo G; Carli G; Koschmieder S; Trotti C; Elli EM; Bonifacio M; Griesshammer M; Sibai H; Harrison C; Palandri F; Ferrer Marín F; Vannucchi AM; Cuevas B; Iurlo A; Alvarez-Larran A; Carobbio A; De Stefano V; Barbui T; Doyle A; Gupta V; Wille K; et alii...

Second cancers in MPN: Survival analysis from an international study. in American journal of hematology / Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22.
2020
ASL Asti
AOU Città della Salute di Torino
AOU Novara

Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Barbui T; Vannucchi AM; Rambaldi A; Alvarez-Larran A; De Stefano V; Griesshammer M; et alii...

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Barbui T; Rambaldi A; Alvarez-Larran A; Vannucchi AM; Marchetti M; Griesshammer M; Isfort S; Recasens V; McMullin MF; Tieghi A; Cacciola R; Benevolo G; Carli G; Fox ML; Beggiato E; Angona A; Perez-Encinas M; Lunghi F; Wille K; Gomez M; Erez D; Rapezzi D; Palova M; Guglielmelli P; Elli EM; Stephenson C; Casetti IC; Rumi E; Patriarca A; et alii...

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. in Leukemia / Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.
2019
ASL Asti
AOU Città della Salute di Torino
AOU Novara

Alvarez-Larran A; Finazzi G; Vannucchi AM; Griesshammer M; Recasens V; Marchetti M; Cacciola R; McMullin MF; Tieghi A; Carli G; Beggiato E; Benevolo G; Fox ML; Lunghi F; Angona A; Wille K; Perez-Encinas M; Gomez M; Erez D; Palova M; Bertolotti L; Elli EM; Guglielmelli P; Casetti IC; Stephenson C; Patriarca A; Rumi E; Bonifacio M; Scaffidi L; et alii...

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. in Annals of hematology / Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.
2018
AOU Città della Salute di Torino

Bensasson C; Guglielmelli P; Sivgin S; Devos T; Callum J; Egyed M; Palandri F; Benevolo G; Saydam G; Griesshammer M; Khan M; Ronco JP; Passamonti F; Griesshammer M; Saydam G; Palandri F; Benevolo G; Egyed M; Callum J; Devos T; Sivgin S; Guglielmelli P; Bensasson C; Khan M; Ronco JP; Passamonti F;

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. in The Lancet. Oncology / Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.
2017
AOU Città della Salute di Torino

Bensasson C; Sivgin S; Vannucchi AM; Callum J; Devos T; Egyed M; Benevolo G; Palandri F; Griesshammer M; Passamonti F; Khan M; Mounedji N; Saydam G;